KeyZell

Executive Summary

KeyZell Biotech is a Spanish biopharmaceutical company founded in 2018, focused on transforming cancer treatment through AI-driven precision oncology. Its lead candidate, LZ-167, is a novel therapeutic designed to selectively target cancer cells while sparing healthy ones, leveraging an artificial intelligence platform to enhance efficacy and reduce toxicity. The company operates across Spain, the UK, Australia, Mexico, and Thailand, positioning itself for global clinical development. With a mission to deliver safer, more effective, and accessible cancer therapies, KeyZell aims to address significant unmet needs in oncology, particularly in solid tumors where current treatments often cause severe side effects and limited efficacy. Currently in the pre-clinical stage, KeyZell is progressing LZ-167 through IND-enabling studies, including pharmacokinetics, toxicology, and manufacturing scale-up. Key upcoming catalysts include the completion of these preclinical studies, which will support an Investigational New Drug (IND) filing, and potential strategic partnerships to accelerate clinical development. While financial details are undisclosed, the company's unique AI-based approach and international footprint provide a differentiated value proposition. Success in these milestones could unlock significant value, but execution risks remain given the early stage of development.

Upcoming Catalysts (preview)

• Q4 2026Completion of IND-Enabling Preclinical Studies for LZ-16770% success
• Q1 2027Filing of Investigational New Drug (IND) Application65% success
• H2 2026Strategic Partnership or Licensing Deal for LZ-16740% success